| Literature DB >> 21880986 |
Harry Z Qui1, Adam T Hagymasi, Suman Bandyopadhyay, Marie-Clare St Rose, Raghunath Ramanarasimhaiah, Antoine Ménoret, Robert S Mittler, Scott M Gordon, Steven L Reiner, Anthony T Vella, Adam J Adler.
Abstract
Cytotoxic CD4 Th1 cells are emerging as a therapeutically useful T cell lineage that can effectively target tumors, but until now the pathways that govern their differentiation have been poorly understood. We demonstrate that CD134 (OX40) costimulation programs naive self- and virus-reactive CD4 T cells to undergo in vivo differentiation into cytotoxic Th1 effectors. CD137 (4-1BB) costimulation maximized clonal expansion, and IL-2 was necessary for cytotoxic Th1 differentiation. Importantly, the T-box transcription factor Eomesodermin was critical for inducing the cytotoxic marker granzyme B. CD134 plus CD137 dual costimulation also imprinted a cytotoxic phenotype on bystanding CD4 T cells. Thus, to our knowledge, the current study identifies for the first time a specific costimulatory pathway and an intracellular mechanism relying on Eomesodermin that induces both Ag-specific and bystander cytotoxic CD4 Th1 cells. This mechanism might be therapeutically useful because CD134 plus CD137 dual costimulation induced CD4 T cell-dependent tumoricidal function in a mouse melanoma model.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21880986 PMCID: PMC3178659 DOI: 10.4049/jimmunol.1101244
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422